Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -24.02% is in line with its 2-year average of -24.01%, around the middle of its 2-year range (-33.18%–-14.46%).
As of the fiscal period ended Tuesday, June 30, 2026. 12.00% above its 12-month average of -27.29%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -24.02%.
RETURN ON EQUITY (ROE)
-24.02%
RETURN ON EQUITY (ROE) AVG TTM
-27.29%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+12.00%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.30%
median of 668 covered companies
CURRENT VS SECTOR MEDIAN
+40.41%
vs the sector median at left
Contineum Therapeutics, Inc.
Market Cap
$470.26M
Return on Equity (ROE)
-24.02%
TTM Avg
-27.29%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$471.64M
Return on Equity (ROE)
-8.21%
TTM Avg
-32.76%
3Y Avg
-79.80%
5Y Avg
-71.61%
Market Cap
$472.23M
Return on Equity (ROE)
8.25%
TTM Avg
6.54%
3Y Avg
3.79%
5Y Avg
3.91%
Market Cap
$469.01M
Return on Equity (ROE)
-56.26%
TTM Avg
-59.48%
3Y Avg
-54.76%
5Y Avg
-34.52%
Market Cap
$475.60M
Return on Equity (ROE)
-9.69%
TTM Avg
-30.79%
3Y Avg
-49.02%
5Y Avg
-53.00%
Market Cap
$478.75M
Return on Equity (ROE)
1.65%
TTM Avg
-27.02%
3Y Avg
-39.92%
5Y Avg
-33.78%
Market Cap
$460.43M
Return on Equity (ROE)
89.43%
TTM Avg
81.07%
3Y Avg
67.39%
5Y Avg
61.90%
Market Cap
$486.60M
Return on Equity (ROE)
19.28%
TTM Avg
28.37%
3Y Avg
24.29%
5Y Avg
382.68%
Market Cap
$493.58M
Return on Equity (ROE)
N/A
TTM Avg
-344.79%
3Y Avg
-198.42%
5Y Avg
-104.57%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | $470.26M | -24.02% | -27.29% | N/A | N/A |
| Bright Minds Biosciences Inc. (DRUG)vs › | $471.64M | -8.21% | -32.76% | -79.80% | -71.61% |
| Kamada Ltd. (KMDA)vs › | $472.23M | 8.25% | 6.54% | 3.79% | 3.91% |
| Sight Sciences, Inc. (SGHT)vs › | $469.01M | -56.26% | -59.48% | -54.76% | -34.52% |
| Cerus Corporation (CERS)vs › | $475.60M | -9.69% | -30.79% | -49.02% | -53.00% |
| Arvinas, Inc. (ARVN)vs › | $478.75M | 1.65% | -27.02% | -39.92% | -33.78% |
| NRC Health (NRC)vs › | $460.43M | 89.43% | 81.07% | 67.39% | 61.90% |
| Puma Biotechnology, Inc. (PBYI)vs › | $486.60M | 19.28% | 28.37% | 24.29% | 382.68% |
| Evolus, Inc. (EOLS)vs › | $493.58M | N/A | -344.79% | -198.42% | -104.57% |
| Oculis Holding AG (OCS)vs › | $495.07M | -36.79% | -82.52% | -55.07% | -25.96% |
ROE
-24.0%
ROA
-23.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -24.02% |
| 2026-03-31 | -23.37% |
| 2025-12-31 | -22.98% |
| 2025-09-30 | -32.91% |
| 2025-06-30 | -33.18% |
| 2025-03-31 | -26.97% |
| 2024-12-31 | -21.34% |
| 2024-09-30 | -16.87% |
| 2024-06-30 | -14.46% |
